Ro 65-5788 (Ceftobiprole medocaril)

Advanz · discontinued Small molecule

Ro 65-5788 (generic name: Ceftobiprole medocaril) is a ceftobiprole medocaril Small molecule drug developed by Advanz. It is currently in discontinued development for Infection of skin AND/OR subcutaneous tissue. Also known as: ceftobiprole.

Ceftobiprole medocaril works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Ceftobiprole medocaril is a small molecule antibiotic in the ceftobiprole class, originally developed by Advanz Pharma and currently owned by Istx. It is used to treat infections of the skin and/or subcutaneous tissue. Ceftobiprole medocaril is off-patent, meaning it is no longer protected by active patents. It is not clear if it has been approved by the FDA. As an off-patent medication, it may be available from generic manufacturers.

At a glance

Generic name	Ceftobiprole medocaril
Also known as	ceftobiprole
Sponsor	Advanz
Drug class	ceftobiprole medocaril
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	discontinued

Mechanism of action

Imagine your body's cells are like buildings, and bacteria are like construction workers. Ceftobiprole medocaril stops the bacteria from building new walls around themselves, which is essential for their survival. Without these walls, the bacteria can't function properly and eventually die.

Approved indications

• Infection of skin AND/OR subcutaneous tissue

Common side effects

No common side effects on file.

Key clinical trials

• Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
• Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. (NA)
• Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
• Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations
• Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age (PHASE3)
• Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria (NA)
• A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin (PHASE1)
• Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ro 65-5788 CI brief — competitive landscape report
• Ro 65-5788 updates RSS · CI watch RSS
• Advanz portfolio CI

Frequently asked questions about Ro 65-5788

What is Ro 65-5788?

Ro 65-5788 (Ceftobiprole medocaril) is a ceftobiprole medocaril drug developed by Advanz, indicated for Infection of skin AND/OR subcutaneous tissue.

How does Ro 65-5788 work?

Ceftobiprole medocaril works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

What is Ro 65-5788 used for?

Ro 65-5788 is indicated for Infection of skin AND/OR subcutaneous tissue.

Who makes Ro 65-5788?

Ro 65-5788 is developed by Advanz (see full Advanz pipeline at /company/advanz).

What is the generic name of Ro 65-5788?

Ceftobiprole medocaril is the generic (nonproprietary) name of Ro 65-5788.

Is Ro 65-5788 also known as anything else?

Ro 65-5788 is also known as ceftobiprole.

What drug class is Ro 65-5788 in?

Ro 65-5788 belongs to the ceftobiprole medocaril class. See all ceftobiprole medocaril drugs at /class/ceftobiprole-medocaril.

What development phase is Ro 65-5788 in?

Ro 65-5788 is in discontinued.

Related

• Drug class: All ceftobiprole medocaril drugs
• Manufacturer: Advanz — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Infection of skin AND/OR subcutaneous tissue
• Also known as: ceftobiprole